FINWIRES · TerminalLIVE
FINWIRES

Nintendo's Fiscal 2026 Profit Jumps 52%; Warns of Tough Year Ahead With Switch Price Hikes

作者

-- Nintendo's (TYO:7974) attributable profit grew 52% in fiscal 2026 on a blowout in sales but foresees a weaker year ahead.

The Kyoto-headquartered game manufacturer's attributable profit rose to 424.1 billion yen in the year through March 31, 2026, from 278.8 billion yen in the previous fiscal year, according to a Friday disclosure to the Tokyo Exchange.

The figure beat the 418.6 billion yen estimate by analysts at Visible Alpha.

Earnings per share jumped to 364.51 yen from 239.47 yen in the preceding year. Visible Alpha analysts estimated earnings per share at 358.51.

Revenue surged 99% to 2.313 trillion yen from 1.165 trillion yen in the previous fiscal year. Despite the surge, the figure failed to meet the forecast of 2.322 trillion yen by Visible Alpha analysts.

Dedicated video game platform sales, including hardware and software, surged 107% to 2.240 trillion yen from 1.084 trillion yen.

Hardware sales of its Pokémon Pokopia game, released in March, jumped to 19.9 million units, while its Mario Kart World software saw sales reach 14.7 million units, including bundle sales.

Sales of the Nintendo Switch, which has reached its 10th year, totaled 3.8 million units, down 65% from the 10.8 million units in fiscal 2025, the game manufacturer said.

Intellectual property sales fell 9.7% year over year to 73.5 billion yen as movie-related revenue declined.

Its spring offering, "Super Mario Galaxy Movie," grossed $800 million worldwide in its first four weeks.

For fiscal 2027, the game manufacturer forecasts net profit to plunge 27% to 310 billion yen and sales to slide 11% to 2.050 trillion yen, taking into account an impact of 100 billion yen from rising component prices, including memory, and tariffs.

Sales of the Nintendo Switch 2, which reached 19.9 million in fiscal 2026, could fall 17% to 16.5 million in fiscal 2027, still signaling "a solid level of adoption" for the device in its second year since launch, the company said.

Nintendo Switch sales are forecast to fall 47% to 2 million units in fiscal 2027, the company said.

Also on Friday, the company announced price adjustments for its Nintendo Switch and Nintendo Switch 2 consoles at home and overseas.

In Japan, effective May 25, the price of Switch 2 will increase 20% to 59,980 yen from 49,980 yen. Nintendo Switch prices will also increase across its OLED, standard and Lite variants.

In the US, Nintendo will hike the price of the Switch 2 to $499.99 from $449.99. The price adjustment for the newer console, starting Sept. 1, will also take effect in Canada and Europe.

The company retained the price of its Nintendo Switch model in the US, Canada and Europe, but warned of further price revisions for the Switch 2 and the standard Switch in other regions.

Nintendo declared a dividend of 177 yen per share, more than double the 85 yen declared in the previous fiscal year. For fiscal 2027, Nintendo could pay a dividend of 162 yen per share.

相关文章

Research

杰富瑞将德文能源的评级从“持有”上调至“买入”,并将目标价从53美元上调至62美元。

根据FactSet调查的分析师报告,德文能源(Devon Energy,股票代码:DVN)的平均评级为“增持”,平均目标价为59.67美元。 (报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们:https://www..com/contact-us)

$DVN
Mining & Metals

Telus第一季度调整后盈利略低于预期,但仍超出预期

Telus (T.TO) 周五公布,第一季度调整后盈利略有下降,但仍超出预期。 经调整后的净利润(已剔除大部分一次性项目)同比下降 8% 至 3.56 亿加元,即每股调整后基本收益 0.23 加元,而去年同期为 3.88 亿加元,即每股收益 0.26 加元。FactSet 调查的分析师此前预期每股收益为 0.22 加元。 合并营业收入和其他收入同比下降 1% 至 50 亿加元,低于去年同期的 51 亿加元,也低于分析师预期的 50.6 亿加元。Telus 表示,合并服务收入增长 1% 被移动设备收入和其他收入的下降所抵消。 该公司报告称,本季度移动和固定用户总数增长 26.2 万,主要得益于新增 1.2 万部移动电话用户、22.9 万台联网设备用户以及 2.1 万互联网用户。 截至第一季度末,Telus Health的全球医疗保健覆盖人数为1.696亿,同比增长9310万。这一增长也反映了Telus去年5月收购Workplace Options后新增的7930万覆盖人数。首席执行官Darren Entwhistle表示,公司正在评估Telus的战略合作伙伴关系,并将把任何变现所得用于降低杠杆率。 Telus将于7月2日向6月10日登记在册的股东派发每股0.4184加元的季度股息。 Telus另行宣布,首席财务官Doug French将于6月30日退休。现任Telus Digital和Telus Health首席财务官Gopi Chande将于7月1日接任。French将继续担任顾问至7月31日,并将担任Telus旗下铁塔公司Terrion的董事会主席。 Telus股票在美国盘前交易中最新下跌0.06美元,至12.84美元。

$T.TO
Asia

市场动态:诺和诺德印度公司4月份销售额增长40%,此前Wegovy和Ozempic产品价格下调。

据彭博新闻周五援引Pharmarack的数据报道,诺和诺德公司4月份在印度的糖尿病和肥胖症药物销量大幅增长,此前该公司下调了Wegovy和Ozempic的价格,以应对来自仿制药索玛鲁肽疗法的日益激烈的竞争。 报道指出,Wegovy、Ozempic及其合作方品牌产品的销量在4月份环比增长40%,达到3.2万支。这是这家丹麦制药集团将起始剂量价格下调至多48%后的首个完整月份。 报道还指出,受低价仿制药索玛鲁肽的推动,印度GLP-1受体激动剂市场整体在4月份环比增长56%,达到41.4万支。礼来公司仍然是印度销量最高的GLP-1受体激动剂生产商。 诺和诺德公司尚未回复的置评请求。 (市场动态新闻来源于与全球市场专业人士的对话。这些信息据信来自可靠来源,但可能包含传闻和推测。准确性无法保证。)

$^BSE$^NSEI